Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Research

Research

                        Center for Tobacco Products Supported Tobacco Regulatory Research Projects
          Research Priorities
          FDA and NIH Study: Population Assessment of Tobacco and Health
          Funding Opportunities Home
          Tobacco Products
          Tobacco Science & Research
          Research
          FDA and NIH Study: Population Assessment of Tobacco and HealthResearch FDA and NIH Study: Population Assessment of Tobacco and Health
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    Print**On this page:**

About the PATH Study
	Research Goals
	Data Access and Availability
	PublicationsPATH - Population Assessment of Tobacco and Health - A collaboration between the NIH and FDA
About the PATH Study

The Population Assessment of Tobacco and Health (PATH) Study is a uniquely large, long-term study of tobacco use and health in the United States. A collaboration between the U.S. Food and Drug Administration (FDA) Center for Tobacco Products and the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA), the study was launched in 2011 and started the first wave of data collection in 2013. For updates on PATH Study data collection, see “PATH Study FAQs for Researchers.”

By following study participants over time, the PATH Study helps scientists learn how and why people start using tobacco, quit using it, and start using it again after they’ve quit, as well as how different tobacco products affect health (such as cardiovascular and respiratory health) over time. Findings from the study may also inform FDA’s actions related to tobacco products, thereby helping to achieve the goals of the Family Smoking Prevention and Tobacco Control Act.

The PATH Study is conducted via a contract awarded to Westat and involves researchers from:

Centers for Disease Control and Prevention
	Center for Tobacco Products, FDA
	Dartmouth College
	National Institute on Drug Abuse, NIH
	New York University
	Roswell Park Cancer Institute
	Rutgers, The State University of New Jersey
	Truth Initiative (formerly Legacy)
	The Medical University of South Carolina
	The University of California, San Diego
	The University of Minnesota
	The University of WaterlooTo learn more, view the “PATH Study 101” video, developed or view the PATH Study Fact Sheet, developed to provide an orientation to the study.

Research Goals for the PATH Study

By monitoring and assessing behaviors, attitudes, biomarkers, and health outcomes associated with tobacco use in the United States, the PATH Study helps enhance the evidence base available to inform FDA’s regulatory activities related to tobacco. Specifically, the study aims to:

Examine what makes people susceptible to using a tobacco product
	Evaluate initiation and use patterns, including the:
	use of newer products, such as  e-cigarettes or ENDS (electronic nicotine delivery systems)
		use of multiple products
		switching from one product to another
	Study patterns of tobacco product use, cessation, and relapse
	Track potential behavioral and health impacts, including biomarkers of exposure and harm
	Assess differences in tobacco-related attitudes, behaviors, and health conditions among racial/ethnic, gender, and age subgroupsData Access and Availability

Data and documentation (questionnaires, codebooks) related to the PATH Study are available on the National Addiction & HIV Data Archive Program (NAHDAP) website including:

PATH Study Fact Sheet Available
	PATH Study Data Tables and Figures: Waves 1 - 5 (2013 – 2019)
	Public-use files (PUFs)from Wave 1 (Sep. 2013–Dec. 2014), Wave 2 (Oct. 2014–Oct. 2015), Wave 3 (Oct. 2015–Oct. 2016), Wave 4 (Dec. 2016—Jan. 2018), Wave 5 (Dec. 2018–Nov. 2019), and Wave 6 (March 2021-Nov. 2021).
	Restricted-use files (RUFs)from Wave 1 (Sep 2013–Dec 2014), Wave 2 (Oct 2014–Oct 2015), Wave 3 (Oct 2015–Oct 2016), Wave 4 (December 2016 – Jan 2018), Wave 5 (Dec. 2018–Nov. 2019), and Wave 6 (March 2021-Nov. 2021), State Design Data, Wave 1 – Wave 5 Tobacco Universal Product Codes, and Wave 2 – Wave 5 State Identifier Data. Qualified researchers are encouraged to apply for access through the NAHDAP website.
	Biomarker Restricted-use files (BRUFs)from Wave 1 (Sep 2013–Dec 2014), Wave 2 (October 2014 – October 2015), Wave 3 (Oct 2015— 2016), and Wave 4 (December 2016 – January 2018) and Wave 5 (Dec. 2018-Nov. 2019).
	Biospecimen Access Program (BAP)which provides the research community with access to urine, serum, and plasma collected from adult PATH Study participants during Wave 1 (Sep. 2013–Dec. 2014).
	Special Collection Restricted-use files (SCRUFs) from Wave 4.5 Youth Only Data Collection; Wave 5.5 Youth and Young Adults ages 13-19 and the PATH Study Adult Telephone Survey (PATH-ATS), ages 20+
	Special Collection Public-use files (SCPUFs) from Wave 4.5 Youth Only Data Collection; Wave 5.5 Youth and Young Adults ages 13-19; and the PATH Study Adult Telephone Survey (PATH-ATS), ages 20+Researchers interested in the PATH Study are encouraged to create an account to join the PATH Study Data User Forum. The forum enables researchers using PATH Study data to submit and answer questions. Announcements, data releases and updates, new publications, upcoming events, and other information for PATH Study data users are also posted to the forum.

Questions about the collection, content, weighting, documentation, or structure of PATH Study data may be submitted to the new Westat email: PATHDataUserQuestions@Westat.com.

NOTE: This email address is not for questions about statistical analysis or analytic guidance. For analytic questions, researchers may wish to consult with statisticians and analysts at their institutions. Additionally, the PATH Study User Forum can be used to obtain feedback and engage in discussion with other PATH Study data users.

PATH Study Publications

Listed below is a selection of peer-reviewed journal articles from the PATH Study. See the NAHDAP website or search PubMed.gov for a complete list of publications.

***Note***: The following publications are highlighted for illustrative purposes only. The information in these highlighted publications is not a formal dissemination of information by FDA and does not represent agency position or policy. The contents of the publications are the responsibility of the authors alone.

Brunette MF, Halenar MJ, Edwards KC, Taylor KA, Emond JA, Tanski SE, et al. Association between tobacco product use and asthma among US adults from the Population Assessment of Tobacco and Health (PATH) Study waves 2-4. BMJ Open Respir Res. 2023;10(1).
	Kasza, K. A., Tang, Z., Xiao, H., Marshall, D., Stanton, C., Gross, A., Jackson, K., Kelley, D., Schroeder, M., Vivar, J., & Hyland, A. (2023). National longitudinal tobacco product discontinuation rates among US youth from the PATH Study: 2013–2019 (waves 1–5). In Tobacco Control (p. tc-2022-057729). BMJ. https://doi.org/10.1136/tc-2022-057729
	Gardner, L.D.; Liu, S.T.; Xiao, H.; Anic, G.M.; Kasza, K.A.; Sharma, E.; Hyland, A.J. Electronic Nicotine Delivery System (ENDS) Device Types and Flavors Used by Youth in the PATH Study, 2016–2019. Int. J. Environ. Res. Public Health 2022, 19, 5236. https://doi.org/10.3390/ijerph19095236
	Kasza, K. A., Tang, Z., Xiao, H., Marshall, D., Stanton, C., Gross, A. L., Jackson, K. M., Kelley, D., Schroeder, M. J., Vivar, J. C., & Hyland, A. (2022). National longitudinal tobacco product cessation rates among US adults from the PATH Study: 2013–2019 (waves 1–5). In Tobacco Control (p. tobaccocontrol-2022-057323). BMJ. https://doi.org/10.1136/tc-2022-057323
	Silveira, M. L., Everard, C. D., Sharma, E., Lauten, K., Alexandridis, A. A., Duffy, K., Taylor, E. V., Tolliver, E. A., Blanco, C., Compton, W. M., Kimmel, H. L., Iafolla, T., Hyland, A., & Chaffee, B. W. (2022). Tobacco Use and Incidence of Adverse Oral Health Outcomes Among US Adults in the Population Assessment of Tobacco and Health Study. JAMA network open, 5(12), e2245909. https://doi.org/10.1001/jamanetworkopen.2022.45909
	Stanton, C. A., Tang, Z., Sharma, E., Seaman, E., Gardner, L. D., Silveira, M. L., Hatsukami, D., Day, H. R., Cummings, K. M., Goniewicz, M. L., Limpert, J., Everard, C., Bansal-Travers, M., Ambrose, B., Kimmel, H. L., Borek, N., Compton, W. M., Hyland, A. J., & Pearson, J. L. (2022). Predictors of e-cigarette and cigarette use trajectory classes from early adolescence to emerging adulthood across four years (2013-2017) of the PATH Study. In Nicotine & Tobacco Research. Oxford University Press (OUP). https://doi.org/10.1093/ntr/ntac119
	Christensen, C. H., Chang, J. T., Rostron, B. L., Hammad, H. T., van Bemmel, D. M., et al. (2021). Biomarkers of Inflammation and Oxidative Stress Among Adult Former Smoker, Current E-Cigarette Users Results from Wave 1 PATH Study. Cancer Epid Biomarkers & Prevention, cebp.0140.2021. https://doi.org/10.1158/1055-9965.epi-21-0140

**Additional Resources**

PATH Study Fact Sheet
	Researcher Information
	Related Research Projects
	Meet Researchers Leading Current Tobacco Research

                                                                                  Content current as of:
      09/21/2023
              
              
Regulated Product(s)
		 TobaccoResearch

          
                        Center for Tobacco Products Supported Tobacco Regulatory Research Projects
          Research Priorities
          FDA and NIH Study: Population Assessment of Tobacco and Health
          Funding Opportunities
 Subscribe to Spotlight on Science
                        Stay current on tobacco regulatory science and research, tobacco scientific publications and study findings, CTP grants, and more in this quarterly newsletter.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop